Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Studyops Inc

Neither a doctor nor a teaching hospital

Research payments

$1,643,233

1,137 payments

Through program year 2025, Studyops Inc is reported as receiving $1,643,233 in research payments, across 1,137 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $210,540 12
2024 Research $89,772 8
2023 Research $421,132 517
2022 Research $451,240 549
2021 Research $216,862 24
2020 Research $123,785 19
2019 Research $129,902 8

Breakdown

Who paid Research payments · program years 2019–2025
  1. Moderna TX, Inc. $772,894 1,029 payments
  2. Allergan Inc. $243,103 25 payments
  3. AbbVie, Inc. $226,430 14 payments
  4. ViiV Healthcare Company $170,292 34 payments
  5. Pfizer Inc. $146,707 16 payments
  6. Biohaven Pharmaceuticals, Inc. $45,046 3 payments
  7. GlaxoSmithKline, LLC. $13,625 2 payments
  8. Sanofi US Services Inc. $12,630 1 payment
  9. Teva Pharmaceuticals USA, Inc. $6,454 11 payments
  10. H. Lundbeck A S $5,329 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $453,978 498 payments
  2. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $318,916 531 payments
  3. A Phase Iiib, Randomized, Multicenter, Active-Controlled, Parallel-Gro $170,292 34 payments
  4. Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine $169,903 10 payments
  5. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $167,623 9 payments
  6. A Phase 23 Randomized Doubleblind Doubledummy Placebo Controlled Study to Evaluate the Safety and Efficacy of 2 Regimens of Orally Administered PF 07321332Ritonavir in Preventing Symptomatic Sarscov2 Infection in Adult Household Contacts of An Individual With Symptomatic Covid19 $108,236 10 payments
  7. A Phase 3, Multicenter, Open-Label 40-Week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Migraine $71,717 15 payments
  8. A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention $45,046 3 payments
  9. M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine $31,590 2 payments
  10. Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine $24,338 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record